Novel Ester and acid derivatives of the 1,5-diarylpyrrole Scaffold as anti-inflammatory and analgesic agents. Synthesis and in vitro and in vivo biological evaluation

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 723-733

  Biava, Mariangela ^a   Porretta, Giulio C ^a   Poce, Giovanna ^a   Battilocchio, Claudio ^a   Manetti, Fabrizio ^b   Botta, Maurizio ^b   Forli, Stefano ^b,i   Sautebin, Lidia ^d   Rossi, Antonietta ^e   Pergola, Carlo ^d   Ghelardini, Carla ^f   Galeotti, Nicoletta ^f   Makovec, Francesco ^g   Giordani, Antonio ^g   Anzellotti, Paola ^h   Patrignani, Paola ^h   Anzini, Maurizio ^b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c European Research Centre for Drug Discovery and Development   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g Rotta Research Laboratorium   (Italy)

^h UNIVERSITY OF CHIETI   (Italy)

ⁱ SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; CARRAGEENAN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOPROPYL 2 METHYL 5 [4 (METHYLSULFONYL)PHENYL] 1 PHENYL 1H PYRROLE 3 ACETATE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; ZYMOSAN;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PAW EDEMA; PRESSURE; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; ROTAROD TEST; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARBOXYLIC ACIDS; CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ESTERS; INHIBITORY CONCENTRATION 50; MACROPHAGES; MICE; PYRROLES;

EID: 77249138784     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901269y     Document Type: Article

References (41)

1. Burke, A.; Smyth, E.; FitzGerald, G. A. Autacoids: Drug Therapy of Inflammation. In The Pharmacological Basis of Therapeutics, 11th ed.; Brunton, L. L., Lazo, J. S., Parker, K. L., Eds.; Macmillan Publishing Co.: New York, 2005; pp 671-736.
2. FitzGerald, G. A.; Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-442.
3. Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vergas, R.; Davis, B.; Day, R.; Ferraz, M. B.; Hawkey, C. J.; Hochberg, M. C.; Kvien, T. K.; Schnitzer, T. J. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N. Engl. J. Med. 2000, 343, 1520-1528.
4. Schnitzer, T. J.; Burmester, G. R.; Mysler, E.; Hochberg, M. C.; Doherty, M.; Ehrsam, E.; Gitton, X.; Krammer, G.; Mellein, B.; Matchaba, P.; Gimona, A.; Hawkey, C. J. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomised controlled trial. Lancet 2004, 364, 676-684.
5. Fries, S.; Grosser, T.; Price, T. S.; Lawson, J. A.; Kapoor, S.; DeMarco, S.; Pletcher, M. T.; Wiltshire, T.; FitzGerald, G. A. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology 2006, 130, 55-64.
6. Grosser, T.; Fries, S.; FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J. Clin. Invest. 2006, 116, 4-15.
7. http://www.emea.europa.eu/pdfs/human/press/pr/PR-Lumiracoxib- 57930107en.pdf, accessed October 29, 2009.
8. Capone, M. L.; Tacconelli, S.; Di Francesco, L.; Sacchetti, A.; Sciulli, M. G.; Patrignani, P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediators 2007, 82, 85-94.
9. Ferdinandi, E. S.; Cayen, M. N.; Pace-Asciak, C. Disposition of etodolac, other anti-inflammatory pyranoindole-1-acetic acids and furobufen in normal and adjuvant arthritic rats. J. Pharmacol. Exp. Ther. 1982, 220, 417-426.
10. Engelhardt, G.; Homma, D.; Schlegel, K.; Utzmann, R.; Schnitzler, C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflammation Res. 1995, 44, 423-433.
11. Weissenbach, R. Clinical trial with Nimesulide, a new non-steroid anti-inflammatory agent, in rheumatic pathology. J. Int. Med. Res. 1981, 9, 349-352.
12. Ku, E. C.; Wasvary, J. M.; Cash, W. D. Diclofenac sodium (GP 45840, Voltaren), a potent inhibitor of prostaglandin synthetase. Biochem. Pharmacol. 1975, 24, 641-643.
13. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Quellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Tagari, P.; Therien, M.; Vickers, P.; Wong, E.; Xu, L. J.; Young, R. N.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The discovery of rofecoxib, [MK 966, Vioxx, 4-(40- methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
14. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide (SC-58635, celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
15. Talley, J. A.; Brown, D. L.; Carter, J. S.;Masferrer,M. J.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seiberk, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]benzenesulfonamide, valdecoxib: A potent and selective inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
16. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; Ethier, D.; Falgueyret, J.-P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, I.; Manacini, J.; Ouellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girad, Y.; Prasit, P.; Zamboni, R.; Rodger, J. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Chan, C.-C. Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-566.
17. Ding, C.; Jones, G. Lumiracoxib (Novartis). IDrugs 2002, 5, 1168-1172.
18. Patrignani, P.; Panara, M. R.; Greco, A.; Fusco, O.; Natoli, C.; Iacobelli, S.; Cipollone, F.; Ganci, A.; Crèminon, C.; Maclouf, J.; Patrono, C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 1994, 271, 1705-1712.
19. Patrignani, P.; Panara, M. R.; Sciulli, M. G.; Santini, G.; Renda, G.; Patrono, C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J. Physiol. Pharmacol. 1997, 48, 623-631.
20. Huntjens, D. R.; Danhof, M.; Della Pasqua, O. E. Pharmacokinetic- pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford, U.K.) 2005, 44, 846-859.
21. Hernandez-Diaz, S.; Varas-Lorenzo, C.; Garcia Rodriguez, L. A. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin. Pharmacol. Toxicol. 2006, 98, 266-274.
22. Kearney, P. M.; Baigent, C.; Godwin, J.; Halls, H.; Emberson, J. R.; Patrono, C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br. Med. J. 2006, 332, 1302-1305.
23. Biava, M.; Porretta, G. C.; Cappelli, A.; Vomero, S.; Botta, M.; Manetti, F.; Giorgi, G.; Sautebin, L.; Rossi, A.; Makovec, F.; Anzini, M. 1,5-Diarylpyrrole-3-acetic acids and esters as novel classes of potent and selective COX-2 inhibitors. J. Med. Chem. 2005, 48, 3428-3432.
24. Biava, M.; Porretta, G. C.; Poce, G.; Supino, S.; Cappelli, A.; Vomero, S.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Ghelardini, C.; Vivoli, E.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Anzini, M. COX-2 inhibitors. 1,5-Diarylpyrrole-3-acetic esters with enhanced inhibitory activity toward COX-2 and improved COX-2/COX-1 selectivity. J. Med. Chem. 2007, 50, 5403-5411.
25. Anzini, M.; Rovini, M.; Cappelli, A.; Vomero, S.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Ghelardini, C.; Norcini, M.; Giordani, A.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Biava,M. Synthesis, biological evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-alkoxyethyl ethers as highly selective COX-2 inhibitors endowed with anti-inflammatory and antinociceptive activity. J. Med. Chem. 2008, 51, 4476-4481.
26. Biava, M.; Porretta, G. C.; Poce, G.; Supino, S.; Manetti, F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Makovec, F.; Anzellotti, P.; Cirilli, R.; Ferretti, R.; Gallinella, B.; La Torre, F.; Anzini, M.; Patrignani, P. Chiral alcohol and et her derivatives of the 1,5-diarylpyrrole scaffold as novel antiinflammatory and analgesic agents. Synthesis, in vitro and in vivo biological evaluation and molecular docking simulations. Bioorg. Med. Chem. 2008, 16, 8072-8081.
27. Cappelli, A.; Anzini, M.; Biava, M.; Makovec, F.; Giordani, A.; Caselli, G.; Rovati, L. C. 3-Substituted-1,5-diaryl-2-alkyl-pyrroles highly selective and orally effective COX-2 inhibitors. PCT Int. Appl. WO2008014821.
28. Biava, M.; Porretta, G. C.; Poce, G.; De Logu, A.; Saddi, M.; Meleddu, R.; Manetti, F.; De Rossi, E.; Botta, M. 1,5-Diphenyl pyrrole derivatives as antimycobacterial agents. Probing the influence on antimycobacterial activity of lipophilic substituents at the phenyl rings. J. Med. Chem. 2008, 51, 3644-3648.
29. Khanna, I. K.; Weier, R. M.; Paul, Y. Y.; Collins, W.; Miyashiro, J. M.; Koboldt, C. M.; Veenhuizen, A. W.; Currie, J. L.; Seibert, K.; Isakson, P. C. 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J. Med. Chem. 1997, 40, 1619-1633.
30. Anzini, M.; Canullo, L.; Braile, C.; Cappelli, A.; Gallelli, A.; Vomero, S.; Menziani, M. C.; De Benedetti, P. G.; Rizzo, M.; Collina, S.; Azzolina, O.; Sbacchi, M.; Ghelardini, C.; Galeotti, N. Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as κ-opioid receptor agonists endowed with antinociceptive and antiamnesic activity. J. Med. Chem. 2003, 46, 3853-3864.
31. Ushiyama, S.; Yamada, T.; Murakami, Y.; Kumakura, S.; Inoue, S.; Suzuki, K.; Nakao, A.; Kawara, A.; Kimura, T. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects. Eur. J. Pharmacol. 2008, 578, 76-86.
32. Gierse, J. K.; Zhang, Y.; Hood, W. F.; Walker, M. C.; Trigg, J. S.; Maziasz, T. J.; Koboldt, C. M.; Muhammad, J. L.; Zweifel, B. S.; Masferrer, J. L.; Isakson, P. C.; Seibert, K. Valdecoxib: Assessment of cyclooxygenase-2 potency and selectivity. J. Pharmacol. Exp. Ther. 2005, 312, 1206-1212.
33. Esser, R.; Berry, C.; Du, Z.; Dawson, J.; Fox, A.; Fujimoto, R. A.; Haston, W.; Kimble, E. F.; Koehler, J.; Peppard, J.; Quadros, E.; Quintavalla, J.; Toscano, K.; Urban, L.; van Duzer, J.; Zhang, X.; Zhou, S.; Marshall, P. J. Preclinical pharmacology of lumiracoxib: A novel selective inhibitor of cyclooxygenase-2. Br. J. Pharmacol. 2005, 144, 538-550.
34. Khanapure, S. P.; Garvey, D. S.; Young, D. V.; Ezawa, M.; Earl, R. A.; Gaston, R. D.; Fang, X.; Murty, M.; Martino, A.; Shumway, M.; Trocha, M.; Marek, P.; Tam, S. W.; Janero, D. R.; Letts, L. G. Synthesis and structure-activity relationship of novel, highly potent metharyl and methcycloalkyl cyclooxygenase-2 (COX-2) selective inhibitors. J. Med. Chem. 2003, 46, 5484-5504.
35. Paramashivappa, R.; Kumar, P. P.; Rao, P. V. S.; Rao, A. S. Design, synthesis and biological evaluation of benzimidazole/ benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 657-660.
36. Warner, T. D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J. A.;Vane, J. R.Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 7563-7568.
37. Tegeder, I.; Lötsch, J.; Krebs, S.; Muth-Selbach, U.; Brune, K.; Geisslinger, G. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin. Pharmacol. Ther. 1999, 65, 533-544.
38. Meller, S. T.; Dykstra, C.; Grzybycki, D.; Murphy, S.; Gebhart, G. F. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 1994, 33, 1471-1478.
39. Zingarelli, B.; Southan, G. J.; Gilad, E.; O'Connor, M.; Salzman, A. L.; Szabó, C. The inhibitory effects of mercaptoalkylguanidines on cyclo-oxygenase activity. Br. J. Pharmacol. 1997, 120, 357-366.
40. Vaught, J.; Pelley, K.; Costa, L. G.; Sether, P.; Enna, S. J. A comparison of the antinociceptive responses to GABA-receptor agonists THIP and baclofen. Neuropharmacology 1985, 24, 211-216.
41. Randal, L. O.; Selitto, J. J. Amethod for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther. 1957, 111, 409-419.